Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jun 25:3:e29244.
doi: 10.4161/onci.29244. eCollection 2014.

Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes

Lidia Robert  1 , Christina Harview  2 , Ryan Emerson  3 , Xiaoyan Wang  4 , Stephen Mok  5 , Blanca Homet  1 , Begonya Comin-Anduix  6 , Richard C Koya  5 , Harlan Robins  3 , Paul C Tumeh  2 , Antoni Ribas  7
Affiliations

Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes

Lidia Robert et al. Oncoimmunology. .

Abstract

Targeting immune inhibitory receptors has brought excitement, innovation and hope to cancer patients. Our recent work revealed the immunological effects of blocking the CTLA4 and PD-1 immune checkpoints on T cell receptor usage among peripheral blood cells, and further uncovers how the expansion of the T cell repertoire matches the immunotoxicity profile of the therapy.

Keywords: CTLA-4; MK-3475; PBMC; PD-1; TCR; Tremelimumab; sequencing.

PubMed Disclaimer

Figures

None
Figure 1. Immunotherapy-specific changes in the absolute number of unique T cell receptor sequences in cancer patient blood lymphocytes. Changes in the T cell receptor (TCR) usage among circulating T cells in the peripheral blood reported between baseline (day 0) and 30 to 60 d following treatment. Data shown are from 21 patients with metastatic melanoma treated with the CTLA-4 blocking antibody tremelimumab (GA, in black), nine with the PD-1 blockade agent MK-3475 (MK, in gray) and four healthy donors (HD, in white).
See this image and copyright information in PMC

References

    1. Robert C, Thomas L, Bondarenko I, O’Day S, M D JW, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517–26. doi: 10.1056/NEJMoa1104621. - DOI - PubMed
    1. Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, Garbe C, Gogas H, Schachter J, Linette G, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013;31:616–22. doi: 10.1200/JCO.2012.44.6112. - DOI - PMC - PubMed
    1. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–54. doi: 10.1056/NEJMoa1200690. - DOI - PMC - PubMed
    1. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369:134–44. doi: 10.1056/NEJMoa1305133. - DOI - PMC - PubMed
    1. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020–30. doi: 10.1200/JCO.2013.53.0105. - DOI - PMC - PubMed